IMUNON Advances IMNN-001 Phase 2 After Favorable Safety Review
LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...
ctDNA
Advertisement
Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Guardant Health Wins FDA Approval for Breast Cancer CDx
Palo Alto, California — September 4, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has...
FDA Grants Accelerated Approval to Etcamah for Breast Cancer
Silver Spring, Maryland, USA, September 4, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
AstraZeneca Wins U.S. Approval for ETCAMAH in Breast Cancer
Cambridge, UK — September 4, 2026 AstraZeneca announced that ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor has received...
Advertisements
Natera Validates Signatera for Lymphoma MRD Assessment
AUSTIN, Texas, September 1, 2026 Natera announced publication of new clinical data in Blood Neoplasia supporting the prognostic and...
Natera Partners With Susan G. Komen to Advance Breast Cancer Awareness
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
HepaRegeniX: FDA Grants Orphan Drug Status to Darizmetinib
Tuebingen, Germany — August 26, 2026 HepaRegeniX GmbH announced that the U.S. FDA has granted Orphan Drug Designation (ODD)...
IMUNON Highlights Phase 3 OVATION 3 Trial at R&D Day
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
NeoGenomics Gains Medicare Coverage for RaDaR ST Monitoring
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
Advertisement
